阿仑单抗治疗的多发性硬化症患者的巨细胞病毒原发性感染。
Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab.
机构信息
Department of Neurology, Hospital Universitario La Princesa, 28002 Madrid, Spain.
Department of Neurology, Hospital Universitario La Princesa, 28002 Madrid, Spain.
出版信息
Mult Scler Relat Disord. 2019 Oct;35:270-271. doi: 10.1016/j.msard.2019.07.026. Epub 2019 Aug 6.
Alemtuzumab is an anti-CD52 monoclonal antibody approved for the treatment of multiple sclerosis (MS). It produces rapid depletion of T and B lymphocytes, which could predispose to opportunistic infections. We report one patient with MS who develops cytomegalovirus (CMV) primary infection after a third cycle of alemtuzumab, with spontaneous recovery associated with rapid lymphocyte reconstitution.
阿仑单抗是一种抗 CD52 单克隆抗体，已获批准用于治疗多发性硬化症（MS）。它可迅速耗竭 T 和 B 淋巴细胞，从而使患者易发生机会性感染。我们报告了 1 例 MS 患者，在接受第 3 个周期的阿仑单抗治疗后发生巨细胞病毒（CMV）原发感染，伴随淋巴细胞快速重建而自发恢复。
Zotero 插件